Monopar Therapeutics (MNPR) EPS (Basic): 2017-2019
Historic EPS (Basic) for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$0.13.
- Monopar Therapeutics' EPS (Basic) fell 30.00% to -$0.13 in Q4 2019 from the same period last year, while for Dec 2019 it was -$0.46, marking a year-over-year decrease of 39.39%. This contributed to the annual value of -$0.45 for FY2019, which is 28.57% down from last year.
- According to the latest figures from Q4 2019, Monopar Therapeutics' EPS (Basic) is -$0.13, which was down 62.50% from -$0.08 recorded in Q3 2019.
- Monopar Therapeutics' 5-year EPS (Basic) high stood at -$0.04 for Q1 2017, and its period low was -$1.68 during Q3 2017.
- Moreover, its 3-year median value for EPS (Basic) was -$0.08 (2019), whereas its average is -$0.22.
- Examining YoY changes over the last 5 years, Monopar Therapeutics' EPS (Basic) showed a top increase of 95.83% in 2018 and a maximum decrease of 125.00% in 2018.
- Over the past 3 years, Monopar Therapeutics' EPS (Basic) (Quarterly) stood at -$0.05 in 2017, then slumped by 100.00% to -$0.10 in 2018, then tumbled by 30.00% to -$0.13 in 2019.
- Its EPS (Basic) was -$0.13 in Q4 2019, compared to -$0.08 in Q3 2019 and -$0.10 in Q2 2019.